Publications

2013

Solomon DA, Kim J-, Bondaruk J, Shariat SF, Wang Z-, Elkahloun AG, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet. 2013;45(12):1428-30.
Yeo H, Lyssiotis CA, Zhang Y, Ying H, Asara JM, Cantley LC, et al. FoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cells. EMBO J. 2013;32(19):2589-602.
Lotan TL, Gumuskaya B, Rahimi H, Hicks JL, Iwata T, Robinson BD, et al. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod Pathol. 2013;26(4):587-603.
Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013;122(15):2673-82.
Bhalla R, Kunju LP, Tomlins SA, Christopherson K, Cortez C, Carskadon S, et al. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol. 2013;26(6):835-48.
Zinn RL, Gardner EE, Dobromilskaya I, Murphy S, Marchionni L, Hann CL, et al. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. Mol Cancer. 2013;12:16.
Kortenhorst MS, Wissing MD, Rodríguez R, Kachhap SK, Jans JJ, Van der Groep P, et al. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. Epigenetics. 2013;8(9):907-20.
Xiong MY, Rizzo AE, Cohen TS, Dyer RK, Korgavkar K, Bingham SF, et al. Predictors of squamous cell carcinoma in high-risk patients in the VATTC trial. J Invest Dermatol. 2013;133(6):1521-32.
Mitsiades CS, Chen-Kiang S. Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. Crit Rev Oncol Hematol. 2013;88 Suppl 1:S5-13.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700